Valuation: Abbott Laboratories (Pakistan) Limited

Market Cap 94.69B 342M 307M 283M 257M 480M 32.49B 486M 3.4B 1.35B 17.03B 1.28B 1.26B 54B P/E 2024
23.2x
P/E 2025 -
Enterprise Value 94.69B 342M 307M 283M 257M 480M 32.49B 486M 3.4B 1.35B 17.03B 1.28B 1.26B 54B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
19.95%
Yield 2024 *
-
Yield 2025 3.81%
1 day+4.65%
1 week+3.37%
Current month+5.42%
1 month+3.62%
3 months+3.15%
6 months+5.18%
Current year-7.90%
1 week 916
Extreme 916
978
1 month 900
Extreme 900
978
Current year 821
Extreme 821
1,274
1 year 821
Extreme 821
1,274
3 years 382.56
Extreme 382.56
1,310
5 years 330
Extreme 330
1,310
10 years 302.1
Extreme 302.1
1,310
Manager TitleAgeSince
Chief Executive Officer - 01/04/2016
Director of Finance/CFO - 01/11/2019
Chief Operating Officer - 01/06/2024
Director TitleAgeSince
Chairman - 30/05/2022
Director/Board Member - 01/03/2009
Director/Board Member - 04/06/2014
Change 5-day change 1-year change 3-year change Capi.($)
+4.65%+3.37%-18.20%+141.79% 342M
+0.22%-0.14%+55.12%+128.82% 1,143B
+0.91%+3.61%+41.21%+84.57% 647B
-0.12%-0.93%+25.59%+106.14% 506B
-1.27%+0.46%+50.82%+63.20% 384B
+0.86%-4.37%+61.16%+37.93% 350B
-0.19%+1.32%+30.03%+51.91% 293B
-0.76%+0.87%+2.56%+24.53% 265B
+0.75%+2.05%+53.85%+71.25% 242B
+0.25%+1.64%+32.05%+107.62% 197B
Average +0.13%+1.03%+33.42%+81.78% 402.79B
Weighted average by Cap. -0.44%+0.71%+42.80%+87.75%

Financials

2024 2025
Net sales 68.18B 246M 221M 204M 185M 346M 23.39B 350M 2.45B 972M 12.26B 924M 905M 38.88B 75.4B 272M 244M 226M 205M 383M 25.87B 387M 2.71B 1.07B 13.56B 1.02B 1B 43B
Net income 5.23B 18.91M 16.97M 15.67M 14.21M 26.56M 1.8B 26.88M 188M 74.61M 941M 70.97M 69.45M 2.99B 7.97B 28.78M 25.83M 23.85M 21.63M 40.42M 2.73B 40.91M 286M 114M 1.43B 108M 106M 4.54B
Net Debt - -
Projected Income Statement - Annual - Abbott Laboratories (Pakistan) Limited
Logo Abbott Laboratories (Pakistan) Limited
Abbott Laboratories Pakistan Limited is engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. The Company operates through four segments: Pharmaceutical, Nutritional, Diagnostic, and Others. It offers treatment options for a number of areas, including the digestive system, heart health, women’s health, respiratory illness, central nervous system/pain and influenza vaccines. Its nutritional brands include Similac, PediaSure, Pedialyte, Ensure, and Glucerna. It offers tests and diagnostic tools, medical diagnostic instruments, automation and informatics solutions for hospitals, reference labs, blood centers, emergency departments, physician offices and clinics. The Company’s easy-to-use test strips require only tiny blood samples while its meters provide results and reports.
Employees
1,380
Date Price Change Volume
27/10/26 PKR 967.16 +4.65% 66,286
26/10/26 PKR 924.15 -0.38% 7,181
23/10/26 PKR 927.67 +0.03% 28,777
22/10/26 PKR 927.37 -1.52% 3,686
21/10/26 PKR 941.66 +0.65% 11,271
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Abbott Laboratories (Pakistan) Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
967.16
Average target price
-

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Abbott Laboratories (Pakistan) Limited
  1. Stock Market
  2. Stocks
  3. ABOT Stock